Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets: Implications for Using Modified Blood Products

Transfusion Medicine Reviews

Volumn 25, Issue 2, 2011, Pages 102-110

  Slichter, Sherrill J ^a   Bolgiano, Douglas ^b   Kao, Kuo Jang ^c   Kickler, Thomas S ^d   McFarland, Janice ^e   McCullough, Jeffrey ^f   Woodson, Robert ^g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BLOOD RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIBODY; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNIZATION; APHERESIS; ARTICLE; CANCER CHEMOTHERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; ULTRAVIOLET B RADIATION;

ANTIBODIES; BLOOD PLATELETS; CYTOTOXINS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IMMUNIZATION; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; MALE; MULTIVARIATE ANALYSIS; PLATELET TRANSFUSION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952693532     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2010.11.002     Document Type: Article

References (19)

1. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997, 337:1861-1869. The Trial To Reduce Alloimmunization To Platelets Study Group.
2. Fuller T.C., Phelan D., Gebel H.M., et al. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 1982, 34:24-29.
3. Visentin G.P., Wolfmeyer K., Newman P.J., et al. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990, 30:694-700.
4. Murphy M.F., Waters A.H. Platelet transfusions: the problem of refractoriness. Blood Rev 1990, 4:16-24.
5. Brand A., Claas F.H., Voogt P.J., et al. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988, 54:160-166.
6. Slichter S.J. Alloimmune refractoriness to transfused platelets. Immunology of transfusion medicine 1994, 597-627. Dekker, Inc., New York. G. Garratty (Ed.).
7. McFarland J.G. Alloimmunization and platelet transfusion. Semin Hematol 1996, 33:315-328.
8. Dutcher J.P., Schiffer C.A., Aisner J., et al. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981, 58:1007-1011.
9. Hussein M.A., Lee E.J., Fletcher R., et al. The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 1996, 87:3959-3962.
10. Slichter S.J. Controversies in platelet transfusion therapy. Ann Rev Med 1980, 31:509-540.
11. Friedberg R.C., Donnelly S.F., Boyd J.C., et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993, 81:3428-3434.
12. Doughty H.A., Murphy M.F., Metcalfe P., et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
13. Alcorta I., Pereira A., Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Br J Haematol 1996, 93:220-224.
14. Legler T.J., Fischer I., Dittmann J., et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 1997, 74:185-189.
15. Levin M.D., de Veld J.C., van der Holt B., et al. Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study. Ann Hematol 2003, 82:357-362.
16. Slichter S.J., Davis K., Enright H., et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
17. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995, 86:3598-3603.
18. Heddle N.M., Blajchman M.A., Meyer R.M., et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002, 42:556-566.
19. Pei R., Wang G., Tarsitani C., et al. Simultaneous HLA class I and class II antibody screening with flow cytometry. Hum Immunol 1998, 59:313-322.